RIO 2019

DCVMN International Annual General Meeting

21-23 October

VACCINES, INNOVATIONS FOR GOOD

Proposed Agenda
Developing Countries Vaccine Manufacturers Network International
20th Annual General Meeting
21-23 October 2019
Rio de Janeiro, Brazil

Page 1 of 5
 DAY 1 - Monday, October 21st
Pre-meetings & Symposia
09:00 - 10:00 Registration 8:00 - 10:00
DCVMN Executive Board/Committee meeting
Private meeting for Executive Committee
members - by invitation only

10:00 – 10:30 Welcome coffee

10:30 - 12:30 Satellite workshop - for DCVMN corporate members only

20 min each Future Vaccine Manufacturing - hosted by Imperial College London’s Future Vaccine Manufacturing
Research Hub & BactiVac
Chair: C. MacLennan*, BactiVac
Co-chair: B. Pierce*, FVMH
Progress in novel vaccine manufacturing platforms and technology transfer
B. Pierce*, FVMH
Baculovirus expression system technology
D. Dat*, Vabiotech
Novel vectors to improve antigen expression systems
S. Gilbert*, Oxford University/VaxHub
Bactivac: catalyst funding for bacterial vaccines
C. MacLennan*, BactiVac
Bioconjugate technology for vaccines
J. Cuccui*, LSHTM
Immunogenic Outer membrane Proteins (OMPs) as potential sub-unit vaccines
C. López Macías*, Bactivac
12:30 - 14:00 Lunch

14:00 – 15:30 Satellite symposium - for all participants

Responsible innovation: cost-effective manufacturing and economies of scale
Hosted by DCVMN Premium Partners
Chair: T. Prusik*, Temptime
Co-chair: M. Lundgren*, GE
14:00 - 14:30 Adapting VVM for the next generation supply chain
T. Prusik*, Temptime
14:30 - 15:00 Vaccine manufacturing technologies and economic considerations.
M. Lundgren*, GE
15:00 - 15:30 Q&A

15:30 - 15:45 Coffee break

15:45 - 17:45 DCVMN General Assembly - for DCVMN Time for networking and private meetings
corporate members only
18:00 – 20:30 Welcome reception for all registered participants

(*) indicates the speaker has confirmed participation

Page 2 of 5
 DAY 2 – Tuesday, October 22nd
08:30 - 09:00 Registration
09:00 - 10:00 Plenary opening session / Gavea Grand Ballroom A&B
09:00 - 10:30 Chair: M. Datla*, Opening address
DCVMN President M. Datla*, DCVMN President
Co-chair: M. Zuma*, Welcome note
Host
M. Zuma*, Bio-Manguinhos/Fiocruz Director
Opening speech
N. Trindade Lima, Fiocruz President
Inaugural address
TBD, Ministry of Health Brazil
Inaugural speech: The roads to universal health coverage
T. Ghebreyesus, WHO Director General

Inaugural keynote lecture: Healthy people, healthy countries

C. F. Etienne*, PAHO Director
10:30 - 11:00 Coffee Break
11:00 - 12:30 Innovation forum / Grand Ballroom
11:00 - 12:30 Inaugural keynote The future decade of immunization
lectures K. O’Brien, WHO
Chair: A. Precioso*, Pandemic influenza, an evolving challenge
Butantan
R. Bright*, BARDA
Co-chair: L. Yang*,
CDIBP Expect the unexpected
R. Hatchett*, CEPI
Achieving equity and sustainability goals through vaccination: leaving no
one behind.
S. Berkley*, Gavi (by video)
12:30 - 14:00 Lunch
14:00 – 15:00 Procurement, financing, and partnerships forum / Grand Ballroom

14:00 - 15:00 Keynote lectures PAHO innovations

Chair: S.Jadhav*, SII J. Barbosa*, PAHO
Co-Chair : S. Yoon,
Engaging industry for accessible, affordable, quality vaccines
LG Chem
E. Kadilli*, UNICEF
Healthy markets: perception and reality
K. Suri*, Panacea
15:00 - 17:30 Voices & choices forum: panel discussions with stakeholders
15:00 – 16:00 Panel discussion I: Public market dynamics
Moderator: J. Chu*, CHAI
Panellists: J. Fitzsimmons*, PAHO, E. Kadili*, UNICEF, M. Zuma*, Bio-Manguinhos/Fiocruz,
S. Jadhav*, SII, D. Hein*, Gavi
16:00 - 16:30 Coffee Break
16:30 - 17:30 Panel discussion II: Access to capital: Removing financial barriers for innovative manufacturing in
developing countries
Moderator: D. Hein*, Gavi
Panellists: J. Yip*, Adjuvant Fund, Y. Kim*, RIGHT Fund, R. A. Oswald*, BMGF, K. Ella*, Bharat, S.
Yoon, LG Chem

Page 3 of 5
17:30 - 18:30 DCVMN elections – Free time for networking - all other participants
members-only event
19:00 - 21:00 Cultural dinner - sponsored by Bio-Manguinhos/Fiocruz for all participants

DAY 3 – Wednesday, October 23rd

09:00 - 10:00 Partnerships forum
Chair: M. Makhoana, Biovac
Cochair: M. Gutierez
PATH’s Center for Vaccine Innovation and Access
D. Kaslow*, PATH
Enhanced international R&D cooperation
A. Wartel*, IVI
Gates Global Health Fund
B. Buckland*, GGHF/NIMBL
10:00 – 10:30 Coffee break

Gavea Ballroom A Gavea Ballroom B

10:30 - 12:30 Catalyzing product development of vaccine Regulatory forum: implementing regulatory
technology innovations: Vaccine Innovation convergence
Prioritization Strategies (VIPS) Chair: N. Dellepiane*, Independent Consultant
Chair: Sotiris Missailidis, Bio- Co-chair: S. Desai*, Zydus Cadila
Manguinhos/Fiocruz
Cochair: S. Gao*, Innovax
Innovations from the VIPS initial prioritisation TBD, ANVISA
phase Impact of WHO Prequalification and Systems on
M. Menozzi-Arnaud*, Gavi access to health
Innovation and rationale for prioritization E. Cooke*, WHO
B. Giersing*, WHO LATAM Regulatory landscape
Information and decision-making for VIPS M L Pombo*, PANDRH/PAHO
D. Kristensen*, PATH Vaccine Safety Blueprint
P. Zuber*, WHO
Panel discussion Updates on Prequalification and KPIs
Moderator: M. Menozzi Arnaud*, Gavi C. Rodriguez*, WHO
Panellists: E. Kadili*, UNICEF, D. Kaslow *, AVAREF progress in clinical trial review and
PATH, S.Gao*, Innovax, S.Prasad*, Bharat, reporting standards”
A.L. Kahn*, WHO Diadé Maiga*, AVAREF/WHO AFRO
12:30 - 14:00 Lunch Private lunch for the newly elected and current
Executive board/committee members
14:00 - 16:00 DCVM future vaccines forum WHO-PAHO-UNICEF global vaccine markets-
Chair: K. Ella*, Bharat Market intelligence
Co-chair: TBD Chair: S. Jadhav*, SII
Co-Chair: T. Cernuschi*, WHO
RNA-based candidate vaccines, Market Intelligence and progress at the global
B. Pierce*, FVMH level: Updates on vaccine self-procuring countries
Novel Shigella vaccine candidates, Tania Cernuschi* , WHO
C. MacLennan*, BMGF MI4A Global Market Studies for HPV,
Meningococcal Meningitis, BGC, D&T and PCV –
Advancements in Chikungunya candidate evolution of the global demand and identified
vaccines risks – WHO (10min – followed by 5 to 10min
R. Ella*, Bharat Q&A)
Novel HPV vaccines, Demand for UNICEF procuring countries –
W. Huang*, Innovax UNICEF SD (10min – followed by 5 to 10min
Novel post-exposure combined vaccination and Q&A)
monoclonals against rabies PAHO work on improving access (10min –

Page 4 of 5
 Sanjeev Kumar* & Kapil Maithal*, Zydus Cadila followed by 5 to 10min Q&A)
Novel Polio vaccines, BioE (tbc) Gavi 5.0 and perspective on future demand –
Zika candidate vaccines, BioM (tbc) (10min – followed by 5 to 10min Q&A)
Panel discussion: “Leveraging market
intelligence and global demand estimates to
support DCVM investment decisions” – (25 min)
Moderator: S. Jadhav*, SII
Panellists include: WHO/EPI, UNICEF, Gavi,
PAHO, BioE and Walvax
16:00 - 16:30 Coffee Break
16:30 - 17:30 Closing session
Chair: A. Homma*, Bio-Manguinhos/Fiocruz
Co-Chair: D. Dat*, Vabiotech
16:30 – 17:30 Closing keynote lecture: Gavea Ballroom A
Equitable vaccine access high on the global health agenda
M. Simao, WHO
Closing remarks, Host of AGM 2020

DAY 4 – Thursday, October 24th

Optional site visit to Fiocruz (tbc)
08:30 Bus pick up from the venue

09:20 Arrival at facilities

09:30 - Visit
11:30
11:30 End of the visit

12:30 Back at the venue

Page 5 of 5